This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (1187)  • Contact me when this article is cited  Related Content  • Related letters  • Related articles  • Similar articles in JAMA  Topic Collections  • Osteoporosis  • Randomized Controlled Trial  • Alert me on articles by topic

Results From a 3-Year Randomized Clinical Trial

Bruce Ettinger, MD; Dennis M. Black, PhD; Bruce H. Mitlak, MD; Ronald K. Knickerbocker, PhD; Thomas Nickelsen, MD; Harry K. Genant, MD; Claus Christiansen, MD; Pierre D. Delmas, MD, PhD; Jose R. Zanchetta, MD; Jacob Stakkestad, MD; Claus C. Glüer, PhD; Kathryn Krueger, MD; Fredric J. Cohen, MD; Stephen Eckert, PhD; Kristine E. Ensrud, MD, MPH; Louis V. Avioli, MD; Paul Lips, MD, PhD; Steven R. Cummings, MD; for the Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

JAMA. 1999;282:637-645.

Context  Raloxifene hydrochloride, a selective estrogen receptor modulator, prevents bone loss in postmenopausal women, but whether it reduces fracture risk in these women is not known.

Objective  To determine the effect of raloxifene therapy on risk of vertebral and nonvertebral fractures.

Design  The Multiple Outcomes of Raloxifene Evaluation (MORE) study, a multicenter, randomized, blinded, placebo-controlled trial.

Setting and Participants  A total of 7705 women aged 31 to 80 years in 25 countries who had been postmenopausal for at least 2 years and who met World Health Organization criteria for having osteoporosis. The study began in 1994 and had up to 36 months of follow-up for primary efficacy measurements and nonserious adverse events and up to 40 months of follow-up for serious adverse events.

Interventions  Participants were randomized to 60 mg/d or 120 mg/d of raloxifene or to identically appearing placebo pills; in addition, all women received supplemental calcium and cholecalciferol.

Main Outcome Measures  Incident vertebral fracture was determined radiographically at baseline and at scheduled 24- and 36-month visits. Nonvertebral fracture was ascertained by interview at 6-month-interim visits. Bone mineral density was determined annually by dual-energy x-ray absorptiometry.

Results  At 36 months of the evaluable radiographs in 6828 women, 503 (7.4%) had at least 1 new vertebral fracture, including 10.1% of women receiving placebo, 6.6% of those receiving 60 mg/d of raloxifene, and 5.4% of those receiving 120 mg/d of raloxifene. Risk of vertebral fracture was reduced in both study groups receiving raloxifene (for 60-mg/d group: relative risk [RR], 0.7; 95% confidence interval [CI], 0.5-0.8; for 120-mg/d group: RR, 0.5; 95% CI, 0.4-0.7). Frequency of vertebral fracture was reduced both in women who did and did not have prevalent fracture. Risk of nonvertebral fracture for raloxifene vs placebo did not differ significantly (RR, 0.9; 95% CI, 0.8-1.1 for both raloxifene groups combined). Compared with placebo, raloxifene increased bone mineral density in the femoral neck by 2.1% (60 mg) and 2.4% (120 mg) and in the spine by 2.6% (60 mg) and 2.7% (120 mg) P<0.001 for all comparisons). Women receiving raloxifene had increased risk of venous thromboembolus vs placebo (RR, 3.1; 95% CI, 1.5-6.2). Raloxifene did not cause vaginal bleeding or breast pain and was associated with a lower incidence of breast cancer.

Conclusions  In postmenopausal women with osteoporosis, raloxifene increases bone mineral density in the spine and femoral neck and reduces risk of vertebral fracture.

Author Affiliations: Division of Research, Kaiser Permanente, Oakland, Calif (Dr Ettinger) and Departments of Epidemiology and Biostatistics (Drs Black and Cummings), Radiology (Dr Genant), and Medicine (Dr Cummings), University of California, San Francisco; Eli Lilly and Co, Indianapolis, Ind (Drs Mitlak, Knickerbocker, Nickelsen, Krueger, Cohen, and Eckert); Center for Clinical and Basic Research, Ballerup, Denmark (Dr Christiansen); INSERM, Lyon, France (Dr Delmas); Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina (Dr Zanchetta); Center for Clinical Osteoporosis Research CECOR AS, Haugesund, Norway (Dr Stakkestad); Department of Diagnostic Radiology, Cristian-Albrechts–Universität Kiel, Germany (Dr Glüer); Veterans Affairs Medical Center, Minneapolis, Minn (Dr Ensrud); Washington University, St Louis, Mo (Dr Avioli); and Vrije Universiteit, Amsterdam, the Netherlands (Dr Lips).

RELATED LETTERS

Raloxifene and Risk of Vertebral Fracture in Postmenopausal Women
J. Halbekath, W. Becker-Brüser, H. Wille, and Bruce Ettinger
JAMA. 2000;283(17):2236-2237.
EXTRACT | FULL TEXT  

Use of Alendronate After 5 Years of Treatment
Susan M. Ott
JAMA. 2007;297(18):1979.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Therapy for Fracture Prevention
Michael R. McClung
JAMA. 1999;282(7):687-689.
EXTRACT | FULL TEXT  

August 18, 1999
JAMA. 1999;282(7):701-702.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of Raloxifene or Tamoxifen Use on Endometrial Cancer Risk: A Population-Based Case-Control Study
DeMichele et al.
JCO 2008;26:4151-4159.
ABSTRACT | FULL TEXT  

The Effects of Tibolone in Older Postmenopausal Women
Cummings et al.
NEJM 2008;359:697-708.
ABSTRACT | FULL TEXT  

Management of breast cancer--Part I
Turner and Jones
BMJ 2008;337:a421-a421.
FULL TEXT  

Usefulness of Computer-Aided Diagnosis Schemes for Vertebral Fractures and Lung Nodules on Chest Radiographs
Kasai et al.
Am. J. Roentgenol. 2008;191:260-265.
ABSTRACT | FULL TEXT  

The Effect of Raloxifene Treatment in Postmenopausal Women with CKD
Ishani et al.
J. Am. Soc. Nephrol. 2008;19:1430-1438.
FULL TEXT  

The 38th David A. Karnofsky Lecture: The Paradoxical Actions of Estrogen in Breast Cancer--Survival or Death?
Jordan
JCO 2008;26:3073-3082.
ABSTRACT | FULL TEXT  

The Rise of Raloxifene and the Fall of Invasive Breast Cancer
Jordan
JNCI J Natl Cancer Inst 2008;100:831-833.
FULL TEXT  

Review of Comparative Effectiveness of Treatments to Prevent Fractures
Stock et al.
ANN INTERN MED 2008;148:885-885.
FULL TEXT  

Multidisciplinary patient education in groups increases knowledge on osteoporosis: A randomized controlled trial
Nielsen et al.
Scand J Public Health 2008;36:346-352.
ABSTRACT  

Osteoporosis: Management and Treatment Strategies for Orthopaedic Surgeons
Gehrig et al.
JBJS 2008;90:1362-1374.
FULL TEXT  

Randomized Trial of Once-Weekly Parathyroid Hormone (1-84) on Bone Mineral Density and Remodeling
Black et al.
J. Clin. Endocrinol. Metab. 2008;93:2166-2172.
ABSTRACT | FULL TEXT  

Gut, inflammation and osteoporosis: basic and clinical concepts
Tilg et al.
Gut 2008;57:684-694.
ABSTRACT | FULL TEXT  

Improving Evaluation and Treatment for Osteoporosis Following Distal Radial Fractures. A Prospective Randomized Intervention
Rozental et al.
JBJS 2008;90:953-961.
ABSTRACT | FULL TEXT  

Persistent Hot Flushes in Older Postmenopausal Women
Huang et al.
Arch Intern Med 2008;168:840-846.
ABSTRACT | FULL TEXT  

ASHP Therapeutic Position Statement on the Prevention and Treatment of Osteoporosis in Adults
MacLaughlin and Raehl
Am J Health Syst Pharm 2008;65:343-357.
FULL TEXT  

Differential Regulation of Native Estrogen Receptor-Regulatory Elements by Estradiol, Tamoxifen, and Raloxifene
Levy et al.
Mol. Endocrinol. 2008;22:287-303.
ABSTRACT | FULL TEXT  

Drugs for pre-osteoporosis: prevention or disease mongering?
Alonso-Coello et al.
BMJ 2008;336:126-129.
FULL TEXT  

Long-term Risk of Incident Vertebral Fractures
Cauley et al.
JAMA 2007;298:2761-2767.
ABSTRACT | FULL TEXT  

Relationship between Bone Mineral Density Changes and Fracture Risk Reduction in Patients Treated with Strontium Ranelate
Bruyere et al.
J. Clin. Endocrinol. Metab. 2007;92:3076-3081.
ABSTRACT | FULL TEXT  

Bone Density in Breast Cancer: When to Intervene?
Gralow
JCO 2007;25:3194-3197.
FULL TEXT  

Raloxifene Enhances Material-Level Mechanical Properties of Femoral Cortical and Trabecular Bone
Allen et al.
Endocrinology 2007;148:3908-3913.
ABSTRACT | FULL TEXT  

The role of DXA bone density scans in the diagnosis and treatment of osteoporosis
Blake and Fogelman
Postgrad. Med. J. 2007;83:509-517.
ABSTRACT | FULL TEXT  

Assessment of non-vertebral fracture risk in postmenopausal women
Roux et al.
Ann Rheum Dis 2007;66:931-935.
ABSTRACT | FULL TEXT  

Patient Assessment in the Diagnosis, Prevention, and Treatment of Osteoporosis
Lata and Elliott
Nutr Clin Pract 2007;22:261-275.
ABSTRACT | FULL TEXT  

Review of Postmenopausal Osteoporosis Pharmacotherapy
Mayes
Nutr Clin Pract 2007;22:276-285.
ABSTRACT | FULL TEXT  

Altered Ovarian Function Affects Skeletal Homeostasis Independent of the Action of Follicle-Stimulating Hormone
Gao et al.
Endocrinology 2007;148:2613-2621.
ABSTRACT | FULL TEXT  

Use of Alendronate After 5 Years of Treatment
Ott
JAMA 2007;297:1979-1979.
FULL TEXT  

Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis
Black et al.
NEJM 2007;356:1809-1822.
ABSTRACT | FULL TEXT  

Hot Flushes, Bone Mineral Density, and Fractures in Older Postmenopausal Women
Huang et al.
Obstet Gynecol 2007;109:841-847.
ABSTRACT | FULL TEXT  

SERMs: Meeting the Promise of Multifunctional Medicines
Jordan
JNCI J Natl Cancer Inst 2007;99:350-356.
ABSTRACT | FULL TEXT  

Twenty-Year Follow-up of the Royal Marsden Randomized, Double-Blinded Tamoxifen Breast Cancer Prevention Trial
Powles et al.
JNCI J Natl Cancer Inst 2007;99:283-290.
ABSTRACT | FULL TEXT  

Selective Activation of Estrogen Receptor-{beta} Transcriptional Pathways by an Herbal Extract
Cvoro et al.
Endocrinology 2007;148:538-547.
ABSTRACT | FULL TEXT  

Osteoporosis and its management
Poole and Compston
BMJ 2006;333:1251-1256.
FULL TEXT  

A 55-Year-Old Woman With Osteopenia
Cummings
JAMA 2006;296:2601-2610.
ABSTRACT | FULL TEXT  

Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
Chatterton et al.
J Endocrinol 2006;191:599-604.
ABSTRACT | FULL TEXT  

Osteoporosis Redux
Lentle and Worsley
JNM 2006;47:1945-1959.
FULL TEXT  

Commentary on Mobley and Others: Importance of Assumptions About VTE Mortality in Modeling the Cost-effectiveness of Osteoporosis Therapies.
Meadows et al.
Med Decis Making 2006;26:633-635.
 

Clinical Applications of Vertebral Fracture Assessment by Dual-Energy X-Ray Absorptiometry
Lewiecki and Laster
J. Clin. Endocrinol. Metab. 2006;91:4215-4222.
ABSTRACT | FULL TEXT  

Skeletal complications of breast cancer therapies.
Hirbe et al.
Clin. Cancer Res. 2006;12:6309s-6314s.
ABSTRACT | FULL TEXT  

Treatment-related osteoporosis in men with prostate cancer.
Smith
Clin. Cancer Res. 2006;12:6315s-6319s.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on the Incidence of Invasive Breast Cancer in Postmenopausal Women with Osteoporosis Categorized by Breast Cancer Risk
Lippman et al.
Clin. Cancer Res. 2006;12:5242-5247.
ABSTRACT | FULL TEXT  

Hemodynamic effects of acute and repeated exposure to raloxifene in ovariectomized sheep
Zoma et al.
Am. J. Physiol. Heart Circ. Physiol. 2006;291:H1216-H1225.
ABSTRACT | FULL TEXT  

Does Vertebroplasty Cause Incident Vertebral Fractures? A Review of Available Data
Trout and Kallmes
Am. J. Neuroradiol. 2006;27:1397-1403.
ABSTRACT | FULL TEXT  

Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO)
Jakob et al.
QJM 2006;99:531-543.
ABSTRACT | FULL TEXT  

Preventing fragility hip fracture in high risk groups: an opportunity missed.
Peng et al.
Postgrad. Med. J. 2006;82:528-531.
ABSTRACT | FULL TEXT  

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.
Barrett-Connor et al.
NEJM 2006;355:125-137.
ABSTRACT | FULL TEXT  

Risk-benefit profiles of raloxifene for women.
Stefanick
NEJM 2006;355:190-192.
FULL TEXT  

Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease Outcomes: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Vogel et al.
JAMA 2006;295:2727-2741.
ABSTRACT | FULL TEXT  

Patient-Reported Symptoms and Quality of Life During Treatment With Tamoxifen or Raloxifene for Breast Cancer Prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 Trial
Land et al.
JAMA 2006;295:2742-2751.
ABSTRACT | FULL TEXT  

Progress in Chemoprevention Drug Development: The Promise of Molecular Biomarkers for Prevention of Intraepithelial Neoplasia and Cancer--A Plan to Move Forward
Kelloff et al.
Clin. Cancer Res. 2006;12:3661-3697.
ABSTRACT | FULL TEXT  

The Cost-effectiveness of Therapy With Teriparatide and Alendronate in Women With Severe Osteoporosis.
Liu et al.
Arch Intern Med 2006;166:1209-1217.
ABSTRACT | FULL TEXT  

Meta-analysis: accuracy of quantitative ultrasound for identifying patients with osteoporosis.
Nayak et al.
ANN INTERN MED 2006;144:832-841.
ABSTRACT | FULL TEXT  

Linking Ligand-Induced Alterations in Androgen Receptor Structure to Differential Gene Expression: A First Step in the Rational Design of Selective Androgen Receptor Modulators
Kazmin et al.
Mol. Endocrinol. 2006;20:1201-1217.
ABSTRACT | FULL TEXT  

Venous thrombosis and conjugated equine estrogen in women without a uterus.
Curb et al.
Arch Intern Med 2006;166:772-780.
ABSTRACT | FULL TEXT  

Cancer-treatment-induced bone loss, part 2
Michaud and Goodin
Am J Health Syst Pharm 2006;63:534-546.
ABSTRACT | FULL TEXT  

Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley et al.
Med Decis Making 2006;26:194-206.
ABSTRACT  

The Effect of Raloxifene after Discontinuation of Long-Term Alendronate Treatment of Postmenopausal Osteoporosis
Michalska et al.
J. Clin. Endocrinol. Metab. 2006;91:870-877.
ABSTRACT | FULL TEXT  

Glucocorticoid-Induced Bone Loss in Dermatologic Patients: An Update
Summey and Yosipovitch
Arch Dermatol 2006;142:82-90.
ABSTRACT | FULL TEXT  

Intervertebral disc height in treated and untreated overweight post-menopausal women
Baron et al.
Hum Reprod 2005;20:3566-3570.
ABSTRACT | FULL TEXT  

Tamoxifen for the Prevention of Myocardial Infarction in Humans: Preclinical and Early Clinical Evidence
Grainger and Schofield
Circulation 2005;112:3018-3024.
FULL TEXT  

Expression Profiling of Rat Femur Revealed Suppression of Bone Formation Genes by Treatment with Alendronate and Estrogen but Not Raloxifene
Helvering et al.
Mol. Pharmacol. 2005;68:1225-1238.
ABSTRACT | FULL TEXT  

Analysis off Estrogen Agonism and Antagonism of Tamoxifen, Raloxifene, and ICI182780 in Endometrial Cancer Cells: A Putative Role for the Epidermal Growth Factor Receptor Ligand Amphiregulin
Gielen et al.
Reproductive Sciences 2005;12:e55-e66.
ABSTRACT  

The prevention of osteoporotic fractures
Karlsson et al.
J Bone Joint Surg Br 2005;87-B:1320-1327.
FULL TEXT  

The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers
Rau et al.
Endocr Relat Cancer 2005;12:511-532.
ABSTRACT | FULL TEXT  

Bazedoxifene Acetate: A Selective Estrogen Receptor Modulator with Improved Selectivity
Komm et al.
Endocrinology 2005;146:3999-4008.
ABSTRACT | FULL TEXT  

Daily and Cyclic Parathyroid Hormone in Women Receiving Alendronate
Cosman et al.
NEJM 2005;353:566-575.
ABSTRACT | FULL TEXT  

Postmenopausal Osteoporosis
Rosen
NEJM 2005;353:595-603.
FULL TEXT  

Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
Hodsman et al.
Endocr. Rev. 2005;26:688-703.
ABSTRACT | FULL TEXT  

Vitamin D Insufficiency Does Not Affect Bone Mineral Density Response to Raloxifene
Antoniucci et al.
J. Clin. Endocrinol. Metab. 2005;90:4566-4572.
ABSTRACT | FULL TEXT  

Hormone replacement therapy: pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: a mini-review
Dietel et al.
Hum Reprod 2005;20:2052-2060.
ABSTRACT | FULL TEXT  

Effect of Raloxifene on Serum Triglycerides in Women With a History of Hypertriglyceridemia While on Oral Estrogen Therapy
Carr et al.
Diabetes Care 2005;28:1555-1561.
ABSTRACT | FULL TEXT  

Raloxifene reduced vertebral fractures and breast cancer regardless of prior hormone therapy use in women
Crandall
Evid. Based Med. 2005;10:84-84.
FULL TEXT  

Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by raloxifene, an antiestrogen with anti-androgen action, but not nimesulide, a selective cyclooxygenase-2 inhibitor
Zeng et al.
Carcinogenesis 2005;26:1109-1116.
ABSTRACT | FULL TEXT  

Estrogen and Raloxifene, a Selective Estrogen Receptor Modulator, Ameliorate Renal Damage in db/db Mice
Chin et al.
Am. J. Pathol. 2005;166:1629-1636.
ABSTRACT | FULL TEXT  

Postmenopausal hormone therapy: from monkey glands to transdermal patches
Davis et al.
J Endocrinol 2005;185:207-222.
ABSTRACT | FULL TEXT  

Hip Fracture in Women without Osteoporosis
Wainwright et al.
J. Clin. Endocrinol. Metab. 2005;90:2787-2793.
ABSTRACT | FULL TEXT  

Treatment of postmenopausal osteoporosis
Reginster
BMJ 2005;330:859-860.
FULL TEXT  

Hormonal Interventions: From Adjuvant Therapy to Breast Cancer Prevention
Dunn
aacredbook 2005;2005:185-188.
FULL TEXT  

Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
Fabian and Kimler
JCO 2005;23:1644-1655.
FULL TEXT  

Tamoxifen Stimulates Cancellous Bone Formation in Long Bones of Female Mice
Perry et al.
Endocrinology 2005;146:1060-1065.
ABSTRACT | FULL TEXT  

Bone Density Screening: A New Level of Evidence?
Cummings
ANN INTERN MED 2005;142:217-219.
FULL TEXT  

Prevention of Hormone-Related Cancers: Breast Cancer
Dunn et al.
JCO 2005;23:357-367.
ABSTRACT | FULL TEXT  

Both estrogen and raloxifene protect against {beta}-amyloid-induced neurotoxicity in estrogen receptor {alpha}-transfected PC12 cells by activation of telomerase activity via Akt cascade
Du et al.
J Endocrinol 2004;183:605-615.
ABSTRACT | FULL TEXT  

Defining the Role of Raloxifene for the Prevention of Breast Cancer
Kalidas et al.
JNCI J Natl Cancer Inst 2004;96:1731-1733.
FULL TEXT  

Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene
Martino et al.
JNCI J Natl Cancer Inst 2004;96:1751-1761.
ABSTRACT | FULL TEXT  

Recommendations for Optimal Care of the Fragility Fracture Patient to Reduce the Risk of Future Fracture
Bouxsein et al.
J Am Acad Orthop Surg 2004;12:385-395.
ABSTRACT | FULL TEXT  

Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis
Bushnell and Goldstein
Neurology 2004;63:1230-1233.
ABSTRACT | FULL TEXT  

Medication Undertreatment in Assisted Living Settings
Sloane et al.
Arch Intern Med 2004;164:2031-2037.
ABSTRACT | FULL TEXT  

Estrogen Plus Progestin and Risk of Venous Thrombosis
Cushman et al.
JAMA 2004;292:1573-1580.
ABSTRACT | FULL TEXT  

Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation
Grady et al.
Obstet Gynecol 2004;104:837-844.
ABSTRACT | FULL TEXT  

Diagnosis of Osteoporotic Vertebral Fractures: Importance of Recognition and Description by Radiologists
Lenchik et al.
Am. J. Roentgenol. 2004;183:949-958.
FULL TEXT  

The Consequences of Exhaustive Antiestrogen Therapy in Breast Cancer: Estrogen-Induced Tumor Cell Death
Osipo et al.
Exp. Biol. Med. 2004;229:722-731.
ABSTRACT | FULL TEXT  

Effects of the Steroidal Aromatase Inhibitor Exemestane and the Nonsteroidal Aromatase Inhibitor Letrozole on Bone and Lipid Metabolism in Ovariectomized Rats
Goss et al.
Clin. Cancer Res. 2004;10:5717-5723.
ABSTRACT | FULL TEXT  

Raloxifene to Prevent Gonadotropin-Releasing Hormone Agonist-Induced Bone Loss in Men with Prostate Cancer: A Randomized Controlled Trial
Smith et al.
J. Clin. Endocrinol. Metab. 2004;89:3841-3846.
ABSTRACT | FULL TEXT  

Classification Algorithms for Hip Fracture Prediction Based on Recursive Partitioning Methods
Jin et al.
Med Decis Making 2004;24:386-398.
ABSTRACT  

National Trends in Osteoporosis Visits and Osteoporosis Treatment, 1988-2003
Stafford et al.
Arch Intern Med 2004;164:1525-1530.
ABSTRACT | FULL TEXT